全球个性化细胞治疗市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球个性化细胞治疗市场 – 行业趋势及 2030 年预测

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Personalized Cell Therapeutic Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 915.65 Million
Diagram Market Size (Forecast Year)
USD 1,779.33 Million
Diagram CAGR
%
Diagram Major Markets Players
  • AbbVie
  • Bausch Health Companies
  • Teva Pharmaceutical Industries Ltd
  • Cipla
  • Lupin

全球个性化细胞治疗市场,按细胞类型(胚胎干细胞、成体干细胞、诱导多能细胞等)、应用(心血管疾病、神经系统疾病、糖尿病、肿瘤学等)、最终用户(医院、家庭护理、专科诊所等)、分销渠道(医院药房、网上药房、零售药房)划分 - 行业趋势和预测到 2030 年。

个性化细胞治疗市场

个性化细胞治疗市场分析及规模

先进疗法和基因传递技术的发展创造了日益激烈的竞争态势,相当多的市场参与者参与了个性化细胞治疗产品的商业化。个性化细胞疗法因外科医生采用该疗法治疗患者而获得了推动。全球个性化细胞疗法市场的需求增加了患者中慢性疾病的患病率。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球个性化细胞治疗市场的增长率。在上述预测期内,全球个性化细胞治疗市场的预期复合年增长率趋于 24.00% 左右。2022 年市场价值为 125.7234 亿美元,到 2030 年将增长至 936.7126 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外,Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

个性化细胞治疗市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 - 2020)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

细胞类型(胚胎干细胞、成体干细胞、诱导性多能细胞、其他)、应用(心血管疾病、神经系统疾病、糖尿病、肿瘤学、其他)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房)

覆盖国家

北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区

涵盖的市场参与者

AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Cipla Inc. (India), Lupin (India), Sun Pharmaceuticals Industries Ltd. (India), Hikma Pharmaceuticals PLC (U.K.), AstraZeneca (U.K.), GSK Plc. (U.K.), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.K.), Alvogen (U.S), F. Hoffmann-La Roche Ltd (Switzerland), Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), Amicus Therapeutics, Inc (U.S.), MeiraGTx Limited (U.S.), Rocket Pharmaceuticals, Inc. (U.S.), Gilead Sciences, Inc. (U.S.)

Market Opportunities

  • Increased Clinical Trials
  • Higher Strategic Alliances

Market Definition

Personalized cells are undifferentiated stem cells that can be divided to generate offspring cells designated as specialized or personalized stem cells. Specialized treatment of numerous chronic diseases such as autoimmune and cancer through vaccinating living cells into the body of patients to boost the personalized cell therapy market. As there are multiple types of living cells such as immature and mature living cell, blood and bone marrow cell and embryonic stem cells that are mainly utilized in personalized cell therapy.

Global Personalized Cell Therapeutic Market Dynamics

Drivers

  • Increasing Economic Burden Due to Neurological Disorders

There are numerous studies conducted on stem cell or personalized cell therapy candidates to treat several neurological disorders and spinal cord injuries. For instance, in September 2016, MAPFRE Foundation declared its first clinical trial results of personalized cell therapy in patients having complete and chronic spinal cord injury. The study led to implanting mesenchymal stem cells that can create different types of tissue to treat the injury.

  • Rising Cases of Chronic Diseases and Cancer

The increasing prevalence of chronic diseases and the collective occurrence of cancer is anticipated to boost the growth of the personalized cell therapy market during the forecast period. For instance, as per the National Cancer Institute (NCI), in 2016, there were an estimated 15.5 million cancer cases that have been occurred in the U.S. Furthermore, as per the records of NCI, in 2017, about 15,270 children and adolescents of the age group of 0 to 19 were diagnosed with cancer in the U.S. Additionally, according to the International Diabetes Federation (IDF), in 2017, over 425 million adults suffered from diabetes worldwide, and this is projected to reach 629 million by 2045. Thus, it boosts market growth.

Opportunities

  • Increased Clinical Trials

Several manufacturers are conducting numerous clinical trials to develop novel personalized cell therapies targeting chronic diseases such as cancer, diabetes, and other autoimmune diseases. For instance, in April 2019, Orgenesis Inc. received Institutional Review Board (IRB) approval to collect liver biopsies from patients at Rambam Medical Center, Israel. The sample will be collected to confirm the safety and efficacy of liver cells for personalized cell replacement therapy in patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. Thus, growing research studies are projected to boost the growth of the global personalized cell therapy market.

  • Higher Strategic Alliances

Several companies are engaged in strategic alliances to boost their offerings in the space, which is projected to strengthen the market competition during the forecast period. For instance, in November 2021, Laurus Labs announced that an agreement was signed to invest in Immunoadoptive Cell Therapy (ImmunoACT), an IIT-Bombay incubated company developing an indigenous CAR T-cell therapy for the treatment of specific types of blood cancers. The Laurus Labs will acquire a 26.62% stake in ImmunoACT for a cash consideration of approximately ₹46 crores.

 Restraints/Challenges

  • Risk of Complications

There is a high risk of complications associated with personalized cell therapies. Complications such as sleep apnea, skin reactions, increased risk of blood clots, and many others are witnessed post the therapy. Thus, it hampers market growth.

  • High Cost

The huge expenditure associated with gene therapies impedes the market growth. Most personalized cell therapeutic products are in the U.S. are covered under reimbursement policies. However, patients who do not have insurance find it difficult to afford such treatments.

This global personalized cell therapeutic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global personalized cell therapeutic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In December 2021, Kite and Daiichi Sankyo Company announced the launch of YESCARTA. It is a chimeric antigen receptor (CAR) T-cell therapy, that will be available to patients suffering from relapsed or refractory large B-cell lymphomas in Japan. 

Global Personalized Cell Therapeutic Market Scope

The global personalized cell therapeutic market is segmented on the basis of cell type, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cell Type

  • Embryonic Stem Cells
  • Adult Stem Cell
  • Induced Pluripotent Cells
  • Others

Application

  • Cardiovascular Diseases
  • Neurological Disorders
  • Diabetes
  • Oncology
  •  Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Personalized Cell Therapeutic Market Regional Analysis/Insights

The global personalized cell therapeutic market is analyzed and market size insights and trends are provided by cell type, application, distribution channel and end-user as referenced above.

The major countries covered in the global personalized cell therapeutic market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing positive growth for the personalized cell therapeutic market throughout the forecast period due to the region's increased R&D activities on personalized cells and well-established healthcare infrastructure.

Asia-Pacific dominates the market due to increased technological advancement and the increasing prevalence of chronic and metabolic diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Personalized Cell Therapeutic Market Share Analysis

个性化细胞治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对个性化细胞治疗市场的关注有关

个性化细胞治疗市场的主要参与者包括:

  • AbbVie Inc.(美国)
  • Bausch Health Companies Inc.(加拿大)
  • Teva Pharmaceutical Industries Ltd.(以色列)
  • Cipla Inc.(印度)
  • 鲁冰花(印度)
  • 太阳制药工业有限公司 (印度)
  • Hikma Pharmaceuticals PLC(英国)
  • 阿斯利康(英国)
  • 葛兰素史克公司(英国)
  • 辉瑞公司(美国)
  • Amneal Pharmaceuticals LLC.(英国)
  • Alvogen(美国)
  • F. Hoffmann-La Roche Ltd(瑞士)
  • 安进公司 (美国)
  • Jazz Pharmaceuticals, Inc.(英国)
  • Amicus Therapeutics, Inc(美国)
  • MeiraGTx Limited(美国)
  • Rocket Pharmaceuticals, Inc.(美国)
  • 吉利德科学公司(美国)

研究方法:全球个性化细胞治疗市场    

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息,请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,涉及数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(Factbook)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Cell Type (Embryonic Stem Cells, Adult Stem Cell, Induced Pluripotent Cells, Others), Application (Cardiovascular Diseases, Neurological Disorders, Diabetes, Oncology, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
The Global Personalized Cell Therapeutic Market size was valued at USD 915.65 USD Million in 2022.
The Global Personalized Cell Therapeutic Market is projected to grow at a CAGR of 24% during the forecast period of 2023 to 2030.
The major players operating in the market include AbbVie ,Bausch Health Companies ,Teva Pharmaceutical Industries Ltd,Cipla ,Lupin,Sun Pharmaceuticals Industries Ltd,Hikma Pharmaceuticals PLC,AstraZeneca,GSK Plc,Pfizer ,Amneal Pharmaceuticals LLC,Alvogen,F. Hoffmann-La Roche Ltd,Amgen ,Jazz Pharmaceuticals,Amicus Therapeutics,MeiraGTx Limited,Rocket Pharmaceuticals,Gilead Sciences, .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.